<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Renal denervation for resistant hypertension - Pisano, A - 2021 | Cochrane Library</title> <meta content="Renal denervation for resistant hypertension - Pisano, A - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011499.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Renal denervation for resistant hypertension - Pisano, A - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011499.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011499.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Renal denervation for resistant hypertension" name="citation_title"/> <meta content="Anna Pisano" name="citation_author"/> <meta content="CNR - Italian National Council of Research" name="citation_author_institution"/> <meta content="Luigi Francesco Iannone" name="citation_author"/> <meta content="Magna Graecia University of Catanzaro" name="citation_author_institution"/> <meta content="Antonio Leo" name="citation_author"/> <meta content="Magna Graecia University of Catanzaro" name="citation_author_institution"/> <meta content="Emilio Russo" name="citation_author"/> <meta content="Magna Graecia University of Catanzaro" name="citation_author_institution"/> <meta content="Giuseppe Coppolino" name="citation_author"/> <meta content="Magna Graecia University of Catanzaro" name="citation_author_institution"/> <meta content="Davide Bolignano" name="citation_author"/> <meta content="Magna Graecia University of Catanzaro" name="citation_author_institution"/> <meta content="davide.bolignano@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD011499.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011499.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011499.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011499.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antihypertensive Agents [therapeutic use]; Blood Pressure; Denervation; *Hypertension [drug therapy]; Kidney [physiology, surgery]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011499.pub3&amp;doi=10.1002/14651858.CD011499.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011499\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011499\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011499.pub3",title:"Renal denervation for resistant hypertension",firstPublishedDate:"Nov 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011499.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011499.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011499.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011499.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011499.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011499.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011499.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011499.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011499.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011499.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4839 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011499.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/appendices#CD011499-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/supinfo/CD011499StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/supinfo/CD011499StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Renal denervation for resistant hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#CD011499-cr-0004">Anna Pisano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#CD011499-cr-0005">Luigi Francesco Iannone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#CD011499-cr-0006">Antonio Leo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#CD011499-cr-0007">Emilio Russo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#CD011499-cr-0008">Giuseppe Coppolino</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information#CD011499-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Davide Bolignano</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information/en#CD011499-sec-0098">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011499.pub3">https://doi.org/10.1002/14651858.CD011499.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011499-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011499-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011499-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011499-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011499-abs-0010">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011499-abs-0001" lang="en"> <section id="CD011499-sec-0001"> <h3 class="title" id="CD011499-sec-0001">Background</h3> <p>Resistant hypertension is highly prevalent among the general hypertensive population and the clinical management of this condition remains problematic. Different approaches, including a more intensified antihypertensive therapy, lifestyle modifications or both, have largely failed to improve patients' outcomes and to reduce cardiovascular and renal risk. As renal sympathetic hyperactivity is a major driver of resistant hypertension, in the last decade renal sympathetic ablation (renal denervation) has been proposed as a possible therapeutic alternative to treat this condition. </p> </section> <section id="CD011499-sec-0002"> <h3 class="title" id="CD011499-sec-0002">Objectives</h3> <p>We sought to evaluate the short‐ and long‐term effects of renal denervation in individuals with resistant hypertension on clinical end points, including fatal and non‐fatal cardiovascular events, all‐cause mortality, hospital admissions, quality of life, blood pressure control, left ventricular hypertrophy, cardiovascular and metabolic profile and kidney function, as well as the potential adverse events related to the procedure. </p> </section> <section id="CD011499-sec-0003"> <h3 class="title" id="CD011499-sec-0003">Search methods</h3> <p>For this updated review, the Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to 3 November 2020: Cochrane Hypertension’s Specialised Register, CENTRAL (2020, Issue 11), Ovid MEDLINE, and Ovid Embase. The World Health Organization International Clinical Trials Registry Platform (via CENTRAL) and the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov were searched for ongoing trials. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. </p> </section> <section id="CD011499-sec-0004"> <h3 class="title" id="CD011499-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) that compared renal denervation to standard therapy or sham procedure to treat resistant hypertension, without language restriction. </p> </section> <section id="CD011499-sec-0005"> <h3 class="title" id="CD011499-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed study risk of bias. We summarised treatment effects on available clinical outcomes and adverse events using random‐effects meta‐analyses. We assessed heterogeneity in estimated treatment effects using Chi² and I² statistics. We calculated summary treatment estimates as a mean difference (MD) or standardised mean difference (SMD) for continuous outcomes, and a risk ratio (RR) for dichotomous outcomes, together with their 95% confidence intervals (CI). Certainty of evidence has been assessed using the GRADE approach. </p> </section> <section id="CD011499-sec-0006"> <h3 class="title" id="CD011499-sec-0006">Main results</h3> <p>We found 15 eligible studies (1416 participants). In four studies, renal denervation was compared to sham procedure; in the remaining studies, renal denervation was tested against standard or intensified antihypertensive therapy. Most studies had unclear or high risk of bias for allocation concealment and blinding.  </p> <p>When compared to control, there was low‐certainty evidence that renal denervation had little or no effect on the risk of myocardial infarction (4 studies, 742 participants; RR 1.31, 95% CI 0.45 to 3.84), ischaemic stroke (5 studies, 892 participants; RR 0.98, 95% CI 0.33 to 2.95), unstable angina (3 studies, 270 participants; RR 0.51, 95% CI 0.09 to 2.89) or hospitalisation (3 studies, 743 participants; RR 1.24, 95% CI 0.50 to 3.11). Based on moderate‐certainty evidence, renal denervation may reduce 24‐hour ambulatory blood pressure monitoring (ABPM) systolic BP (9 studies, 1045 participants; MD ‐5.29 mmHg, 95% CI ‐10.46 to ‐0.13), ABPM diastolic BP (8 studies, 1004 participants; MD ‐3.75 mmHg, 95% CI ‐7.10 to ‐0.39) and office diastolic BP (8 studies, 1049 participants; MD ‐4.61 mmHg, 95% CI ‐8.23 to ‐0.99). Conversely, this procedure had little or no effect on office systolic BP (10 studies, 1090 participants; MD ‐5.92 mmHg, 95% CI ‐12.94 to 1.10). Moderate‐certainty evidence suggested that renal denervation may not reduce serum creatinine (5 studies, 721 participants, MD 0.03 mg/dL, 95% CI ‐0.06 to 0.13) and may not increase the estimated glomerular filtration rate (eGFR) or creatinine clearance (6 studies, 822 participants; MD ‐2.56 mL/min, 95% CI ‐7.53 to 2.42).  </p> </section> <section id="CD011499-sec-0007"> <h3 class="title" id="CD011499-sec-0007">Authors' conclusions</h3> <p>In patients with resistant hypertension, there is low‐certainty evidence that renal denervation does not improve major cardiovascular outomes and renal function. Conversely, moderate‐certainty evidence exists that it may improve 24h ABPM and diastolic office‐measured BP. Future trials measuring patient‐centred instead of surrogate outcomes, with longer follow‐up periods, larger sample size and more standardised procedural methods are necessary to clarify the utility of this procedure in this population. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011499-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011499-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011499-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011499-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011499-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011499-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011499-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD011499-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011499-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011499-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011499-abs-0002" lang="en"> <h3>Renal denervation for improving outcomes in individuals with resistant hypertension</h3> <p><b>Key messages:</b> </p> <p>We don’t know if using renal denervation can improve risks to the heart, blood vessels and kidneys in people with resistant hypertension.  </p> <p>However, renal denervation might be effective in lowering blood pressure in people with resistant hypertension.  </p> <p><b>What is resistant hypertension?</b> </p> <p>Resistant hypertension is a condition in which high blood pressure levels continue even after several blood pressure‐lowering (antihypertensive) medicines have been given at high doses. It is estimated that 10% to 20% of people with hypertension have resistant hypertension.  </p> <p><b>What did we want to find out?</b> </p> <p>Renal denervation is a treatment that involves destroying renal nerves through a minimally invasive catheter‐based technique to treat high blood pressure. We wanted to know if renal denervation would safely reduce blood pressure and improve quality of life in people with resistant hypertension. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared renal denervation to other treatments or no treatment for who have resistant hypertension. </p> <p><b>What did we find?</b> </p> <p>We found 15 studies that involved over 1400 people with resistant hypertension and lasted from 3 to 24 months. </p> <p><b>Main results:</b> </p> <p>So far, we don’t know if using renal denervation can improve risks to the heart, blood vessels and kidneys in people with resistant hypertension. On the other hand, renal denervation might be effective in lowering blood pressure in people with resistant hypertension.  </p> <p><b>What are the main limitations of the evidence?</b> </p> <p>More studies that look at factors important to patients such as quality of life are needed. Studies that last longer and have more participants are needed to find out if denervation can lower blood pressure. </p> <p><b>How up to date is the evidence?</b> </p> <p>The review updates our previous review. The evidence is up to date to November 2020</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011499-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011499-sec-0088"></div> <h3 class="title" id="CD011499-sec-0089">Implications for practice</h3> <section id="CD011499-sec-0089"> <p>The evidence accrued so far is insufficient to support the use of renal denervation as a clinically useful procedure for improving cardiovascular outcomes in patients with resistant hypertension. In contrast, a moderate‐quality body of evidence suggests that this procedure may result in a reduction in blood pressure levels, although it probably increases the risk of bradycardia episodes. </p> </section> <h3 class="title" id="CD011499-sec-0090">Implications for research</h3> <section id="CD011499-sec-0090"> <p>Focussed trials, powered for patient‐centred instead of surrogate outcomes, with longer follow‐up periods, larger sample sizes, more standardised procedural methods and, possibly, examining particular subgroups of patients with resistant hypertension (e.g. subjects with different cardiovascular or renal risk profiles) are needed to clarify the optimal target population for this procedure. Study design providing a sham control procedure and blinded outcome assessors are indispensable for minimising bias and improving the reliability of findings. Results from ongoing trials testing alternative methods for performing renal nerve ablation, e.g. focussed ultrasounds, the administration of neurotoxic agents, cryotherapy or brachytherapy are also awaited. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011499-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011499-sec-0008"></div> <div class="table" id="CD011499-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Renal denervation versus sham denervation or standard treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with resistant hypertension<br/><b>Setting:</b> outpatient<b> </b> <br/><b>Intervention:</b> renal denervation<br/><b>Comparison:</b> sham procedure or standard treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Effect estimate<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sham denervation/</b> </p> <p><b>Standard treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Renal denervation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000 (6 to 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.31 (0.45 to 3.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>742</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ischaemic stroke</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 1000 (4 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98 (0.33 to 2.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>892</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unstable angina</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000 (2 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.51 (0.09 to 2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>28 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>35 per 1000 (14 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.24 (0.50 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>743</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic 24‐hour ABPM (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic 24‐hour ABPM ranged across control groups from 139 to 157.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic 24‐hour ABPM in the intervention groups was on average <b>5.29 lower</b> (95%CI ‐10.46 to ‐0.13) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1045<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic 24‐hour ABPM (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic 24‐hour ABPM ranged across control groups from 80 to 89.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic 24‐hour ABPM in the intervention groups was on average <b>3.75 lower</b> (95%CI ‐7.10 to ‐0.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1004<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic office BP (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic office BP ranged across control groups from 140 to 165.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic office BP in the intervention groups was on average <b>5.92 lower</b> (95%CI ‐12.94 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1090<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic office BP (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic office BP ranged across control groups from 83.8 to 99.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic office BP in the intervention groups was on average <b>4.61 lower</b> (95%CI ‐8.23 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR or creatinine clearance (mL/min/1.73m²)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean eGFR or creatinine clearance ranged across control groups from 70.59 to 92.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean eGFR or creatinine clearance in the intervention groups was on average <b>2.56 lower</b> (95%CI ‐7.53 to 2.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum creatinine (mg/dL)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum creatinine ranged across control groups from 0.86 to 1.07</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum creatinine in the intervention groups was on average <b>0.03 higher</b> (95%CI ‐0.06 to 0.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>721<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>*The <b>assumed risk</b> is the observed risk in the reference (control) group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: We are very uncertain about the estimate. </p> <p><b>Legend</b><br/><sup>ABPM: ambulatory blood pressure monitoring<br/>BP: blood pressure<br/>CI: confidence interval<br/>CV: cardiovascular<br/>eGFR: estimated glomerular filtration rate<br/>MD: mean difference<br/>NA: information not available (data sparse or absent)<br/>RR: risk ratio</sup>. </p> <p>1. Downgraded 1 level for serious imprecision: Wide confidence intervals</p> <p>2. Downgraded 1 level because outcome reported by less than half of the studies</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011499-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011499-sec-0009"></div> <section id="CD011499-sec-0010"> <h3 class="title" id="CD011499-sec-0010">Description of the condition</h3> <p>Resistant or refractory hypertension (RH) is characterised by blood pressure levels persistently above target, in spite of the concurrent use of three antihypertensive agents of different classes at best‐tolerated doses, including a diuretic (<a href="./references#CD011499-bbs2-0187" title="CalhounDA , JonesD , TextorS , GoffDC , MurphyTP , TotoRD , et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation2008;117(25):e510-26.">Calhoun 2008</a>). Data from cross‐sectional and hypertension outcome studies suggest that this condition is not infrequent, with an estimated prevalence of 10% to 20% in the general hypertensive population (<a href="./references#CD011499-bbs2-0199" title="MyatA , RedwoodSR , QureshiAC , SpertusJA , WilliamsB . Resistant hypertension. BMJ2012;345:e7473.">Myat 2012</a>). Individuals with resistant hypertension are 50% more likely to experience poor outcomes and adverse cardiovascular events than those with controlled hypertension (<a href="./references#CD011499-bbs2-0196" title="JuddE , CalhounDA . Apparent and true resistant hypertension: definition, prevalence and outcomes. Journal of Human Hypertension2014;28(8):463-8. [DOI: 10.1038/jhh.2013.140]">Judd 2014</a>). The lack of efficacy of multiple interventions in addition to pharmacological therapy, including dietary and lifestyle modifications, emphasises the importance of finding new effective and safe treatments for treating this condition. </p> </section> <section id="CD011499-sec-0011"> <h3 class="title" id="CD011499-sec-0011">Description of the intervention</h3> <p>Renal sympathetic denervation comprises the ablation of renal afferent and efferent nerves through a minimally invasive, catheter‐based percutaneous intervention performed via femoral access. This is achieved by a thermal increase generated by the application of low‐dose radiofrequency or focussed ultrasound energy that is effective in disrupting large portions of nervous fibres located within the adventitia of the renal artery. Alternative ways to ablate renal nerves, including the administration of neurotoxic agents, cryotherapy or brachytherapy are currently under investigation. </p> </section> <section id="CD011499-sec-0012"> <h3 class="title" id="CD011499-sec-0012">How the intervention might work</h3> <p>Sympathetic hyperactivity has long been acknowledged as a major player in the genesis of resistant hypertension (<a href="./references#CD011499-bbs2-0195" title="HuanY , CohenDL . Renal denervation: a potential new treatment for severe hypertension. Clinical Cardiology2013;36(1):10-4.">Huan 2013</a>). In studies conducted in the eighties, surgical sympathectomy was effective in some individuals in lowering blood pressure and symptoms associated with severe hypertension. However, this procedure is no longer used because of considerable side effects (<a href="./references#CD011499-bbs2-0198" title="LeongKT , WaltonA , KrumH . Renal sympathetic denervation for the treatment of refractory hypertension. Annual Review of Medicine2014;65:349-65.">Leong 2014</a>). As with sympathectomy, renal denervation might improve blood pressure control by reducing abnormal renal adrenergic nerve activity. Furthermore, since other conditions, such as congestive heart failure, atrial fibrillation, sleep breathing disorders, and diabetes mellitus are all associated with an overactive sympathetic drive, this procedure might result in pleiotropic benefits, including improvements in glycaemic levels, sleep apnoea, arrhythmias, and oxidative stress (<a href="./references#CD011499-bbs2-0157" title="WitkowskiA , PrejbiszA , FlorczakE , KadzielaJ , SliwinskiP , BielenP , et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension2011;58:559-65. ">Witkowski 2011</a>). Of note, in spontaneously hypertensive rats, renal denervation was able to ameliorate metabolic control and to prevent hypertensive stroke and brain injury, in addition to controlling blood pressure (<a href="./references#CD011499-bbs2-0200" title="NakagawaT , HasegawaY , UekawaK , MaM , KatayamaT , SuetaD , et al. Renal denervation prevents stroke and brain injury via attenuation of oxidative stress in hypertensive rats. Journal of the American Heart Association2013;2(5):e000375.">Nakagawa 2013a</a>; <a href="./references#CD011499-bbs2-0201" title="KatayamaT , SuetaD , KataokaK , HasegawaY , KoibuchiN , ToyamaK , et al. Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome. Journal of the American Heart Association2013;2(4):e000197.">Nakagawa 2013b</a>). </p> </section> <section id="CD011499-sec-0013"> <h3 class="title" id="CD011499-sec-0013">Why it is important to do this review</h3> <p>As shown in a milestone meta‐analysis, renal denervation reduced mean blood pressure at six months in individuals with persistent hypertension; intra‐procedural complications, including renal artery dissection and femoral pseudoaneurysms, were rare (<a href="./references#CD011499-bbs2-0188" title="DavisMI , FilionKB , ZhangD , EisenbergMJ , AfilaloJ , SchiffrinEL , et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. Journal of the American College of Cardiology2013;16(3):231-41.">Davis 2013</a>). Unfortunately, data were mostly derived from observational, uncontrolled studies with limited follow‐up, small sample sizes, and high heterogeneity in blood pressure measurement. Since then, randomised controlled trials (RCTs) (<a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>) evaluated the effectiveness of this procedure in treating RH with variable results. In more recent meta‐analyses including RCTs, renal denervation did not produce significant benefit on blood pressure control in individuals with persistent hypertension (<a href="./references#CD011499-bbs2-0190" title="Fadl ElmulaM ,  Feng Y-M,  JacobsL ,  LarstorpAC ,  KjeldsenSE ,  PersA ,  European Network COordinating research on Renal Denervation (ENCOReD). Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure2017;26(4):195-203.">Fadl Elmula 2017</a>, <a href="./references#CD011499-bbs2-0186" title="AgasthiP , ShipmanJ , ArsanjaniR , AshukemM , GirardoME , YerasiC , et al. Renal denervation for resistant hypertension in the contemporary era: a systematic review and meta-analysis. Scientific Reports2019;9(1):6200.">Agasthi 2019</a>). Whether BP control really benefits from renal denervation, and whether this procedure might impact hard outcomes, such as mortality and cardiovascular events, remains unknown at this time. Over the past year, new evidence, based on larger RCTs and long‐term data on the efficacy of renal denervation on surrogate and hard end points, is now accruing, showing promising results. Therefore, an updated assessment of the efficacy and safety profile of this procedure is mandatory to define whether the benefits of implementing renal denervation in the clinical management of individuals with resistant hypertension outweigh the harms. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011499-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011499-sec-0014"></div> <p>To evaluate the short‐ and long‐term effects of renal sympathetic denervation in individuals with resistant hypertension on: </p> <p> <ul id="CD011499-list-0001"> <li> <p>patient‐centred end points, including cardiovascular morbidity and mortality, all‐cause mortality, hospital admissions, and quality of life; </p> </li> <li> <p>blood pressure control;</p> </li> <li> <p>cardiovascular and metabolic profile;</p> </li> <li> <p>kidney function;</p> </li> <li> <p>adverse events, including but not limited to bradycardia, hypotension episodes, femoral artery pseudoaneurysm, and renal artery dissection. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011499-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011499-sec-0015"></div> <section id="CD011499-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011499-sec-0017"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth, or other predictable methods) of individuals with resistant hypertension undergoing renal sympathetic denervation procedures, without duration or language restrictions. </p> </section> <section id="CD011499-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (older than 18 years), with refractory or resistant hypertension, defined by the presence of a clinic blood pressure above target (higher than 140/90 mmHg, or higher than 130/80 mmHg in individuals with type 2 diabetes mellitus), despite the concomitant use of three or more antihypertensive drugs of different classes, including a diuretic. </p> </section> <section id="CD011499-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any transcatheter renal sympathetic denervation procedures performed using contemporary percutaneous catheters compared with standard medical therapy or sham intervention. </p> </section> <section id="CD011499-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We considered a set of primary and secondary outcomes, according to clinical importance:</p> <section id="CD011499-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011499-list-0002"> <li> <p>Fatal and non‐fatal cardiovascular events, including but not limited to myocardial infarction, cerebrovascular accidents, and congestive heart failure </p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Any hospitalisation and duration of hospital stay (if long‐term data are available)</p> </li> <li> <p>Quality of life (assessed using validated scales or any other instrument as reported by authors, such as the Short‐Form Health Survey (SF‐36) </p> </li> </ul> </p> </section> <section id="CD011499-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011499-list-0003"> <li> <p>Blood pressure control (change in ABPM and clinic systolic, diastolic, and mean blood pressure) </p> </li> <li> <p>Left ventricular hypertrophy</p> </li> <li> <p>Atrial fibrillation episodes</p> </li> <li> <p>Obstructive sleep apnoea severity (apnoea‐hypopnoea index)</p> </li> <li> <p>Kidney function (change in serum creatinine, glomerular filtration rate (GFR), proteinuria or albuminuria, need for renal replacement therapy) </p> </li> <li> <p>Metabolic profile (change in lipid and blood glucose levels and insulin resistance indices) </p> </li> <li> <p>Withdrawal due to adverse effects, including but not limited to bradycardia and hypotensive episodes, femoral artery pseudoaneurysm, renal artery dissection, transient dizziness, pitting oedema, flank pain, and anaemia </p> </li> </ul> </p> </section> </section> </section> <section id="CD011499-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011499-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this updated review, the Cochrane Hypertension Information Specialist conducted systematic searches in the following databases for randomised controlled trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD011499-list-0004"> <li> <p>the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (to 3 November 2020); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (Issue 10, 2020) via Cochrane Register of Studies (to 3 November 2020); </p> </li> <li> <p>Ovid MEDLINE(R) and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions(R) (to 2 November 2020); </p> </li> <li> <p>Ovid Embase (to 2 November 2020);</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (to 3 November 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (via CENTRAL) (to 3 November 2020). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b. (<a href="./references#CD011499-bbs2-0194" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD011499-sec-0094">Appendix 1</a>. </p> </section> <section id="CD011499-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD011499-list-0005"> <li> <p>The Cochrane Hypertension Information Specialist searched the Hypertension Specialised Register segment (which includes searches of MEDLINE and Epistemonikos for systematic reviews) to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. </p> </li> <li> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. </p> </li> <li> <p>Where necessary, we contacted authors of key papers and abstracts to request additional information about their trials. </p> </li> <li> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of hypertension. We considered adverse effects described in included studies only. </p> </li> <li> <p>We checked the reference lists of cardiology and nephrology textbooks for additional resources. </p> </li> </ul> </p> </section> </section> <section id="CD011499-sec-0026"> <h3 class="title" id="CD011499-sec-0026">Data collection and analysis</h3> <section id="CD011499-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two authors (AL and LFI) independently screened titles and abstracts, and retained studies and reviews that might include relevant data or information on trials for review in detail; studies that were not applicable were excluded. The same authors (AL and LFI) independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD011499-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two authors (AL and LFI) independently carried out data extraction using a standard electronic data extraction form. We arranged for translations of studies reported in non‐English language journals before assessment. If more than one publication of a study existed, we grouped the reports together and used the publication with the most complete data in the analyses. If relevant outcomes were published only in earlier versions of the study, we used such data. </p> </section> <section id="CD011499-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (AL and LFI) independently assessed the following items using the risk of bias assessment tool (<a href="./references#CD011499-bbs2-0194" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>), which contained the following domains: </p> <p> <ul id="CD011499-list-0006"> <li> <p>Sequence generation (selection bias);</p> </li> <li> <p>Allocation concealment (selection bias);</p> </li> <li> <p>Blinding:</p> <ul id="CD011499-list-0007"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias);</p> </li> </ul> </li> <li> <p>Completeness of outcome data (attrition bias);</p> </li> <li> <p>Selective outcome reporting (reporting bias);</p> </li> <li> <p>Other sources of bias: e.g. funding bias.</p> </li> </ul> </p> </section> <section id="CD011499-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous outcome results as risk ratios (RRs) with 95% confidence intervals (CIs). Where continuous scales of measurement were used to assess the effects of treatment, we reported results as mean differences (MDs) or standardised mean differences (SMDs) if different scales were reported, with 95% CI. </p> </section> <section id="CD011499-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We appraised unit of analysis issues according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011499-bbs2-0194" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). For studies with more than two arms, we included only arms that met the inclusion criteria of the review. There were no further unit of analysis issues as no‐cluster RCTs or crossover studies have been found.  </p> </section> <section id="CD011499-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We requested additional information from the corresponding author(s) by email. We carefully evaluated important data, such as numbers of screened and randomised participants, as well as numbers of intention‐to‐treat, as‐treated, and per‐protocol populations. We explored attrition in the study, such as dropouts, losses to follow‐up, and withdrawals. We appraised issues of missing data and imputation methods (such as last‐observation‐carried‐forward) according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011499-bbs2-0194" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). </p> </section> <section id="CD011499-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity with a Chi² test on n ‐ 1 degrees of freedom, using an alpha of 0.05 for statistical significance, and used the I² statistic (<a href="./references#CD011499-bbs2-0193" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We considered I² values of 25%, 50%, and 75% to correspond to low, medium, and high levels of heterogeneity. </p> </section> <section id="CD011499-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Where possible, we had planned to construct funnel plots to assess for the potential existence of small study bias (<a href="./references#CD011499-bbs2-0194" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). </p> </section> <section id="CD011499-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We analysed data for each outcome using Review Manager Web (<a href="./references#CD011499-bbs2-0202" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) in an attempt to estimate the overall effect. Data were pooled using random‐effects meta‐analysis, but the fixed‐effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD011499-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned subgroup analyses to explore possible sources of heterogeneity including:</p> <p> <ul id="CD011499-list-0008"> <li> <p>participants (age, race)</p> </li> <li> <p>type of intervention (type of catheter employed and technique used)</p> </li> <li> <p>type of comparator (standard therapy, sham, other denervation procedure)</p> </li> <li> <p>presence/absence of diabetes </p> </li> <li> <p>presence/absence of CV disease</p> </li> <li> <p>severity of renal function impairment</p> </li> <li> <p>duration and severity of hypertension (number and dosage of antihypertensive drugs used) </p> </li> </ul> </p> <p>We had also planned an exploration of the effect of short‐ and long‐term follow‐up as a source of significant heterogeneity between studies. </p> <p>However, due to the few number of studies eventually included, the majority of these subgroup analyses was not feasible. </p> </section> <section id="CD011499-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned sensitivity analyses to explore the influence of the following factors on the effect size: </p> <p> <ul id="CD011499-list-0009"> <li> <p>repeating the analysis excluding any large studies, to establish how much they impacted on the results; </p> </li> <li> <p>repeating the analysis taking into account the risk of bias;</p> </li> <li> <p>repeating the analysis excluding unpublished studies.</p> </li> </ul> </p> </section> <section id="CD011499-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We had planned to construct a summary table via the GRADEpro‐GDT(<a href="./references#CD011499-bbs2-0191" title="GRADEpro Guideline Development Tool. Version (accessed prior to 25 October 2021). Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2015. www.guidelinedevelopment.org.">GRADEpro GDT 2015</a>), reporting: </p> <p> <ul id="CD011499-list-0010"> <li> <p>a summary of findings from all the primary outcomes and a summary of findings from some secondary outcomes, that have been pre‐selected according to their clinical importance. These included cardiovascular outcomes (myocardial infarction, ischaemic stroke, unstable angina), hospital admission, blood pressure outcomes (24 h‐ABPM and office blood pressure) and renal function (serum creatinine and eGFR). </p> </li> <li> <p>the certainty of the body of evidence supporting each of these outcomes using the GRADE approach (<a href="./references#CD011499-bbs2-0191" title="GRADEpro Guideline Development Tool. Version (accessed prior to 25 October 2021). Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2015. www.guidelinedevelopment.org.">GRADEpro GDT 2015</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011499-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011499-sec-0039"></div> <section id="CD011499-sec-0040"> <h3 class="title">Description of studies</h3> <p>The literature search is current to 3 November 2020.</p> <section id="CD011499-sec-0041"> <h4 class="title">Results of the search</h4> <p>The search identified 2749 records; we also identified five more records from additional searches or handsearches. Full‐text assessment of 259 records for this updated review resulted in the inclusion of 15 eligible studies (88 articles), comprising a total of 1416 participants (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0004" title="FranzenKF , MortensenK , HimmelF , StritzkeJ , KoesterJ , BockJ , et al. Percutaneous renal denervation (PRD) improves central hemodynamics and arterial stiffness - a pilot study. European Heart Journal2012;33:771. ">Franzen 2012</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), and 25 ongoing trials (27 articles; <a href="./references#CD011499-bbs2-0161" title="NCT01874470. Renal denervation by Allegro system in patients with resistant hypertension. clinicaltrials.gov/show/NCT01874470 (first received 2013). ">ALLEGRO‐HTN</a>; <a href="./references#CD011499-bbs2-0162" title="NCT01522430. Denervation of renal sympathetic activity and hypertension study. clinicaltrials.gov/show/NCT01522430 (first received 2012). ">DEPART</a>; <a href="./references#CD011499-bbs2-0163" title="NCT01903187. Multi-center, randomized, single-blind, sham controlled clinical investigation of renal denervation for uncontrolled hypertension. clinicaltrials.gov/show/NCT01903187 (first received 2013). ">EnligHTN IV</a>; <a href="./references#CD011499-bbs2-0164" title="NCT02102126. Effect of renal denervation on arterial stiffness and haemodynamics in patients with uncontrolled hypertension (ENSURE). clinicaltrials.gov/show/NCT02102126 (first received 2014). ">ENSURE</a>; <a href="./references#CD011499-bbs2-0165" title="NCT02002585. Renal protection using sympathetic denervation in patients with chronic kidney disease (Kidney protection study - KPS Study). clinicaltrials.gov/show/NCT02002585 (first received 2013). ">KPS</a>; <a href="./references#CD011499-bbs2-0166" title="NCT01848275. Full length versus proximal renal arteries ablation. clinicaltrials.gov/show/NCT01848275 (first received 2011). ">NCT01848275</a>; <a href="./references#CD011499-bbs2-0167" title="NCT01918111. Effects of renal denervation for resistant hypertension on exercise diastolic function and regression of atherosclerosis and the evaluation of new methods predicting a successful renal sympathetic denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT trial from RENEWAL RDN Registry). clinicaltrials.gov/show/NCT01918111 (first received 2013). ">NCT01918111</a>; <a href="./references#CD011499-bbs2-0168" title="NCT01968785. Renal denervation in patients with uncontrolled blood pressure. clinicaltrials.gov/show/NCT01968785 (first received 2013). ">NCT01968785</a>; <a href="./references#CD011499-bbs2-0169" title="NCT02021019. Renal denervation to improve outcomes in patients with end-stage renal disease. clinicaltrials.gov/show/NCT02021019 (first received 2014). ">NCT02021019</a>; <a href="./references#CD011499-bbs2-0170" title="NCT02346045. Effect of renal denervation in end stage renal disease with resistant hypertension. clinicaltrials.gov/show/NCT02346045 (first received 2014). ">NCT02346045</a>; <a href="./references#CD011499-bbs2-0171" title="NCT02444442. The Australian SHAM controlled clinical trial of renal denervation in patients with resistant hypertension (AUSHAM RDN-01). clinicaltrials.gov/show/NCT02444442 (first received 2015). ">NCT02444442</a>; <a href="./references#CD011499-bbs2-0172" title="NCT02608632. High frequency guided renal artery denervation for improving outcome of renal ablation procedure. clinicaltrials.gov/show/NCT02608632 (first received 2015). ">NCT02608632</a>; <a href="./references#CD011499-bbs2-0173" title="LiuZ , ShenL , HuangW , ZhaoX , FangW , WangC , et al. Efficacy and safety of renal denervation for Chinese patients with resistant hypertension using a microirrigated catheter: study design and protocol for a prospective multicentre randomised controlled trial. BMJ Open2017;7(9):e015672. ">NCT02900729</a>; <a href="./references#CD011499-bbs2-0174" title="NTR3444. Endovascular renal sympathetic denervation versus spironolactone in treatment-resistant hypertension: a randomized, multicentric study (RRSS trial). www.trialregister.nl/trialreg/admin/rctview.asp?TC=3444 (first received 2012). ">NTR3444</a>; <a href="./references#CD011499-bbs2-0175" title="NCT01895140. A study of renal denervation in patients with treatment resistant hypertension. clinicaltrials.gov/ct2/show/NCT01895140 (first received 2013). ">PaCE</a>; <a href="./references#CD011499-bbs2-0176" title='AziziM , BasileJ , DaemenJ , DaviesJ , FrancisD , KirtaneA , et al. The "rADIANCE-HTN" clinical study: a two-cohort study design to evaluate the effectiveness of the paradise renal denervation system in patients with hypertension. Journal of the American Society of Hypertension2016;10(4 Suppl):e39. NCT02649426. A study of the ReCor Medical Paradise system in clinical hypertension (RADIANCE-HTN). clinicaltrials.gov/show/NCT02649426 (first received 2016). '>RADIANCE‐HTN</a>; <a href="./references#CD011499-bbs2-0177" title="NCT01939392. Rapid renal sympathetic denervation for resistant hypertension using the OneShot renal denervation system II (RAPID II). clinicaltrials.gov/show/NCT01939392 (first received 2013). ">RAPID II</a>; <a href="./references#CD011499-bbs2-0178" title="NCT01865240. Renal denervation for resistant hypertension. clinicaltrials.gov/show/NCT01865240 (first received 2013). ">RDNP‐2012‐01</a>; <a href="./references#CD011499-bbs2-0179" title="NCT01617551. Effect of renal denervation on no-mediated regulation of salt and water excretion, vasoactive hormones and tubular transport proteins in patients with resistant hypertension (RENO). clinicaltrials.gov/show/NCT01617551 (first received 2012). ">RENO</a>; <a href="./references#CD011499-bbs2-0180" title="NCT01785732. Renal sympathetic denervation and insulin sensitivity (RENSYMPIS study). clinicaltrials.gov/show/NCT01785732 (first received 2013). ">RENSYMPIS</a>; <a href="./references#CD011499-bbs2-0181" title="NCT01762488. Renal denervation in treatment resistant hypertension, a double-blind randomized controlled trial (ReSET-2). clinicaltrials.gov/show/NCT01762488 (first received 2013). ">ReSET‐2</a>; <a href="./references#CD011499-bbs2-0182" title="NCT01737138. Safety and effectiveness study of percutaneous catheter-based renal sympathetic denervation in patients with chronic kidney disease and resistant hypertension. clinicaltrials.gov/show/NCT01737138 (first received 2012). ">RSD4CKD</a>; <a href="./references#CD011499-bbs2-0183" title="NCT03758196. Renal sympathetic denervation from the adventitia on resistant hypertension (RSDARH）. clinicaltrials.gov/show/NCT03758196 (first received 29 November 2018 ). ">RSDARH</a>; <a href="./references#CD011499-bbs2-0184" title="NCT01713270. Safety and effectiveness study of percutaneous catheter-based renal sympathetic denervation in patients with drug-resistant hypertension and symptomatic atrial fibrillation. clinicaltrials.gov/show/NCT01713270 (first received 2012). QiuM , YinY , ShanQ . Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial. Trials2013;14:168. ">RSDforAF</a>; <a href="./references#CD011499-bbs2-0185" title="NCT01972139. Renal denervation in patients with uncontrolled hypertension - SYMPLICITY HTN-4. clinicaltrials.gov/show/NCT01972139 (first received 2013). ">SYMPLICITY HTN‐4</a>). We contacted the authors of some of the included studies for additional information about study methods and unreported data; five investigators responded to our queries (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>). <a href="#CD011499-fig-0001">Figure 1</a> depicts the flow of study selection. </p> <div class="figure" id="CD011499-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011499-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011499-sec-0042"> <h4 class="title">Included studies</h4> <p>All fifteen included studies were parallel‐group RCTs with adult participants (<a href="./references#CD011499-sec-0104" title="">Characteristics of included studies</a>). Study duration ranged from three to 24 months. All studies except <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>, <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>, and <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> excluded patients with estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m². The renal sympathetic denervation procedure was performed with the electrode radiofrequency Symplicity catheter system in 11 studies (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). Ablation was performed with an off‐the‐shelf saline‐irrigated radiofrequency catheter in <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>. In <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a> and <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>, ablation was made with the EnligHTN™ multi‐electrode denervation system. In <a href="./references#CD011499-bbs2-0004" title="FranzenKF , MortensenK , HimmelF , StritzkeJ , KoesterJ , BockJ , et al. Percutaneous renal denervation (PRD) improves central hemodynamics and arterial stiffness - a pilot study. European Heart Journal2012;33:771. ">Franzen 2012</a>, details of the denervation procedure were not provided. In seven studies, a series of four to six ablations per renal artery was performed (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). Four ablations simultaneously were delivered at the mid/distal segment of the renal artery by <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a> and <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>. In <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>, an average of eight (range 6 to 11) radiofrequency ablations were applied per renal artery. The number of ablations was not reported in five studies (<a href="./references#CD011499-bbs2-0004" title="FranzenKF , MortensenK , HimmelF , StritzkeJ , KoesterJ , BockJ , et al. Percutaneous renal denervation (PRD) improves central hemodynamics and arterial stiffness - a pilot study. European Heart Journal2012;33:771. ">Franzen 2012</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). In four studies, renal denervation was compared to sham procedure (<a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). <a href="./references#CD011499-bbs2-0004" title="FranzenKF , MortensenK , HimmelF , StritzkeJ , KoesterJ , BockJ , et al. Percutaneous renal denervation (PRD) improves central hemodynamics and arterial stiffness - a pilot study. European Heart Journal2012;33:771. ">Franzen 2012</a>, <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>, <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>, <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>, <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>, and <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> compared renal denervation plus antihypertensive medications with antihypertensive medications alone. In five studies, the effects of renal denervation plus standard antihypertensive therapy were tested against an intensified pharmacological regimen (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>, <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>). One trial (<a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>) randomly divided subjects into three equal groups according to the supplementation to the previously administered medication (M‐group, B‐group, D‐group). Outcomes available from studies were: incidence of myocardial infarction (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>), ischaemic stroke (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>), unstable angina (<a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>), all‐cause‐mortality and hospitalisations (<a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>), quality of life (self‐reported health status)( <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>), 24‐hour ambulatory blood pressure monitoring (ABPM) (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), daytime and/or night‐time ABPM (<a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), office BP (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), home BP (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>), left ventricular hypertrophy (<a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>) and kidney function (serum creatinine, eGFR) (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), glucose metabolism measures (<a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). Only <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> reported on obstructive sleep apnea (OSA) severity. In addition, <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; and <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> looked systematically at the incidence of adverse effects associated to the procedure. </p> </section> <section id="CD011499-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 1056 records, 912 of which were excluded at title and abstract screening (<a href="#CD011499-fig-0001">Figure 1</a>). One hundred and forty‐four records were excluded after full‐text evaluation. Reasons for exclusion were: inappropriate population, problem, or both (294 reports); inappropriate intervention, outcome, or both (463 reports); not an RCT (48 reports); editorial, comment, letter or review articles without reporting randomised trial data (251 reports). See <a href="./references#CD011499-sec-0105" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD011499-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>We have shown summaries of the risks of bias in the included studies in <a href="#CD011499-fig-0002">Figure 2</a> and <a href="#CD011499-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011499-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011499-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011499-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011499-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011499-sec-0045"> <h4 class="title">Allocation</h4> <p>The overall risk of selection bias was highly variable. Random sequence generation was detailed in seven studies with a low risk of bias (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>), while there were insufficient data to inform assessment in the remainder. Only two of the included studies adequately described the allocation concealment methodologies that were applied (<a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>); this information was not stated in the remainder. </p> </section> <section id="CD011499-sec-0046"> <h4 class="title">Blinding</h4> <p>The risk of performance and detection bias was also variable. Eight studies were fully open‐label, thus allowing a high risk of both biases (<a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a> was an open‐label trial but outcome assessors were blinded to the procedure. <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a> was double‐blinded; participants and personnel were unaware of treatment arm, while blinding of outcome assessment was not stated. In <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a> and <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>, participants and outcome assessors were blinded to the treatment. In <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>, patients were blinded to renal denervation or sham procedure, while outcome assessor blinding was unclear. In <a href="./references#CD011499-bbs2-0004" title="FranzenKF , MortensenK , HimmelF , StritzkeJ , KoesterJ , BockJ , et al. Percutaneous renal denervation (PRD) improves central hemodynamics and arterial stiffness - a pilot study. European Heart Journal2012;33:771. ">Franzen 2012</a> and <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>, no overall information on blinding was specified. </p> </section> <section id="CD011499-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>The overall dropout rate ranged from 3% to 37% with no differences among groups, with the exception of <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>, <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a> and <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>, in which dropouts were more prevalent in the treatment arm, and in <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>, in which 31 participants (62%) dropped out from the control group. Three studies reported no dropouts (<a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>). The information provided on attrition bias was insufficient to permit assessment in three studies (<a href="./references#CD011499-bbs2-0004" title="FranzenKF , MortensenK , HimmelF , StritzkeJ , KoesterJ , BockJ , et al. Percutaneous renal denervation (PRD) improves central hemodynamics and arterial stiffness - a pilot study. European Heart Journal2012;33:771. ">Franzen 2012</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>). Seven studies were analysed on an intention‐to‐treat basis (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). In <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a> and <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>, analyses were performed on a per‐protocol basis. In <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a> and <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>, results were analysed on both a per‐protocol and intention‐to‐treat basis. </p> </section> <section id="CD011499-sec-0048"> <h4 class="title">Selective reporting</h4> <p>All the predefined outcomes were reported in 11 studies (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). Some prespecified outcomes were not reported in <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a> (office BP, serum creatinine) or in <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a> (daytime and night‐time BP, dipping status, diastolic and systolic ventricular function, left ventricular hypertrophy, renal sodium excretion, pulse wave velocity, a 25% or more decline in eGFR). Possible selective reporting was unclear in the remainder. </p> </section> <section id="CD011499-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>Seven studies declared funding from industry (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). In <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a> and <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>, the authors stated that the sponsor had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. In <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>, the involvement of industry was unclear. In <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>, <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>, and <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>, the authors declared that data were monitored, collected, and managed by the sponsor. In <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>, an author received personal fees from Medtronic during the conduct of the study. No other sources of apparent bias were noticed in the other studies. </p> </section> </section> <section id="CD011499-sec-0050"> <h3 class="title" id="CD011499-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD011499-tbl-0001"><b>Summary of findings 1</b> Summary of findings</a> </p> <p>The main effects of renal denervation on the primary outcomes and on the most important secondary outcomes are summarised in <a href="./full#CD011499-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD011499-sec-0051"> <h4 class="title">Primary outcomes</h4> <section id="CD011499-sec-0052"> <h5 class="title">Non‐fatal cardiovascular events</h5> <p>In a meta‐analysis of four studies (742 participants), renal denervation may have little or no effect on the risk of myocardial infarction compared to sham or standard treatment (RR 1.31, 95% CI 0.45 to 3.84; <a href="./references#CD011499-fig-0004" title="">Analysis 1.1</a>); there was no heterogeneity (Chi² = 0.79; P = 0.85; I² = 0%; <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). In data pooled from five studies (892 participants), renal denervation may have little or no effect on the risk of ischaemic stroke compared to no treatment (RR 0.98, 95% CI 0.33 to 2.95; <a href="./references#CD011499-fig-0005" title="">Analysis 1.2</a>); there was no heterogeneity (Chi² = 1.86; P = 0.76; I² = 0%; <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). In a meta‐analysis of three studies (270 participants), renal denervation may have little or no effect on the risk of unstable angina compared to sham or standard therapy (RR 0.51, 95% CI 0.09 to 2.89; <a href="./references#CD011499-fig-0006" title="">Analysis 1.3</a>); there was no heterogeneity (Chi² = 0.0.44; P = 0.80; I² = 0%; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>). </p> </section> <section id="CD011499-sec-0053"> <h5 class="title">All‐cause mortality</h5> <p>Data on all‐cause mortality were provided by two studies; in <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>, two patients in the renal denervation group and one in the sham group died. No deaths were recorded by <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a> during the 24‐month follow‐up. </p> </section> <section id="CD011499-sec-0054"> <h5 class="title">Hospitalisation</h5> <p>Data on hospitalisation were reported by three studies. In a meta‐analysis of three studies (743 participants), renal denervation may have little or no effect on the risk of hospitalisation compared to sham or standard treatment (RR 1.24, 95% CI 0.50 to 3.11; <a href="./references#CD011499-fig-0007" title="">Analysis 1.4</a>); there was no heterogeneity (Chi² = 1.00; P = 0.61; I² = 0%; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). </p> <p><a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a> recorded hospital admissions for atrial fibrillation episodes and for new‐onset of heart failure; otherwise, in <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a> and <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>, patients required hospitalisation to adjust antihypertensive medication. </p> </section> <section id="CD011499-sec-0055"> <h5 class="title">Quality of life</h5> <p>Data on quality of life (self‐reported health status) were only available in <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>. After six‐month follow‐up, the self‐reported health status was 53.8 ± 22.3 in the control group and 75.0 ± 14.1 (baseline‐adjusted between‐group difference: 13.6 ;95% CI ‐7.4 to 34.6; P = 0.28). </p> </section> </section> <section id="CD011499-sec-0056"> <h4 class="title">Secondary outcomes</h4> <section id="CD011499-sec-0057"> <h5 class="title">24‐hour ambulatory blood pressure monitoring (ABPM)</h5> <p>Twenty‐four hour ABPM was measured in 13 studies (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; (<a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>); <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). In a meta‐analysis of nine studies (10 subgroups) (1045 participants) (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), renal denervation may reduce systolic 24‐hour ABPM when compared with sham or standard therapy (MD ‐5.29 mmHg, 95% CI ‐10.46 to ‐0.13; <a href="./references#CD011499-fig-0008" title="">Analysis 1.5</a>). The high heterogeneity found in this analysis (Chi² = 39.14; P &lt; 0.0001; I² = 77%) was fully dependent on the type of radiofrequency system, multi‐electrode instead of a single electrode catheter (I² = 6%). In data pooled from eight studies (9 subgroups) (1004 participants) (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), renal denervation may reduce diastolic 24‐hour ABPM as compared to sham or standard therapy (MD ‐3.75 mmHg, 95% CI ‐7.10 to ‐0.39; <a href="./references#CD011499-fig-0009" title="">Analysis 1.6</a>). There was high heterogeneity in this latter analysis (Chi² = 29.75, P = 0.0002; I² = 73%) that was reduced by selecting studies using different radiofrequency system (I² = 59%). </p> <p>In <a href="./references#CD011499-bbs2-0011" title="AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): 40 patient analysis. Circulation2012;1(126):A17520. AhmedH , NeuzilP , SchejbalovaM , BejrM , KralovecS , ReddyVY . Renal sympathetic denervation for the management of chronic hypertension (RELIEF): an interim analysis. Heart Rhythm2012;1:S469-70. NCT01628172. Renal sympathetic denervation for the management of chronic hypertension [Renal sympathetic denervation for the management of chronic hypertension]. clinicaltrials.gov/show/NCT01628172 (first received 2012). ">RELIEF 2012</a>, the 24‐hour systolic/diastolic BP decreased by ‐17/‐12 mmHg (P = 0.006/P = 0.001) in the bilateral renal denervation group versus ‐5/‐5 mmHg (P = 0.22/P = 0.42) in the sham control group. In <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a> , renal denervation (RD) and spironolactone addition (15 participants in both arms) showed a similar reduction in 24‐hour systolic/diastolic ABPM after 24‐month follow‐up (‐12.9/‐7.1 (RD) versus ‐13.9/‐7.0 mmHg (control). In <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>, spironolactone was superior to renal denervation (RDN) in reducing both 24‐hour SBP, ‐23.6 mmHg (‐31.9 to ‐15.3) versus ‐5.7 mmHg (‐14.8 to 3.4) and 24‐hour DBP, ‐10.2 (‐14.4 to ‐6.1) versus ‐3.7 (‐8.2 to 0.9), after six‐month follow‐up. <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a> recorded no difference between groups in 24‐hour diastolic BP (‐3.8 mmHg, 95% CI ‐8.3 to 0.6; P = 0.091). In <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>, the mean change for the 24‐hour systolic BP was −7.0 mmHg (95% CI −10.8 to −3.2) for patients undergoing renal denervation and −3.5 mmHg (95% CI −6.7 to −0.2) in the sham group (P = 0.15), as analysed on an intention‐to‐treat basis. In the per‐protocol population, the change in 24‐hour systolic BP at six months was −8.3 mmHg (95% CI −11.7 to −5.0) for patients undergoing renal denervation and −3.5 mmHg (95% CI −6.8 to −0.2) in the sham group (P = 0.042). No changes in 24‐hour diastolic BP were recorded in either the intention‐to‐treat or per‐protocol analysis. All these single‐study data were directly retrieved from the correspondent papers. </p> </section> <section id="CD011499-sec-0058"> <h5 class="title">Daytime ABPM</h5> <p>In separate meta‐analyses of five studies (234 participants), renal denervation may have no effect over standard treatment in reducing, respectively, systolic (MD 3.87 mmHg, 95% CI ‐5.02 to 12.76; I² = 70%; <a href="./references#CD011499-fig-0010" title="">Analysis 1.7</a>) and diastolic daytime ABMP (MD 2.93 mmHg, 95% CI ‐3.22 to 9.08; I² = 76%; <a href="./references#CD011499-fig-0011" title="">Analysis 1.8</a>) (<a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). Heterogeneity could not be further explored for the paucity of the studies included. </p> <p>In <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>, RD and sham groups had similar reductions at six months in daytime SBP and DBP compared, respectively, with baseline (SBP ‐6.1 ± 18.9 mmHg versus ‐4.3 ± 15.1 mmHg, P = 0.66; DBP ‐3.2 ± 10.8 versus ‐3.6 ± 8.3, P = 0.87). </p> </section> <section id="CD011499-sec-0059"> <h5 class="title">Night‐time ABPM</h5> <p>In separate meta‐analyses of five studies (234 participants), renal denervation may have little or no effect on systolic (MD ‐1.65 mmHg, 95% CI ‐12.74 to 9.45; I² = 75%; <a href="./references#CD011499-fig-0012" title="">Analysis 1.9</a>) and diastolic night‐time ABPM (MD ‐1.08 mmHg, 95% CI ‐9.25 to 7.08; I² = 87%; <a href="./references#CD011499-fig-0013" title="">Analysis 1.10</a>) when compared with standard therapy (<a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>). Heterogeneity could not be further explored for the paucity of the studies included. </p> <p>In <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>, after six‐month follow‐up, changes in night‐time SBP, (‐1.4 ± 18.2 mmHg (RD) versus ‐1.1 ± 14.4 mmHg (SHAM), P = 0.95) and DBP (‐0.6 ± 10.1 (RDN) versus ‐0.7 ± 8.8 (SHAM), P = 0.97) were very similar in both groups. In <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>, after six‐month follow‐up, the mean change in night‐time SBP was ‐6.1 ± 18.2 mmHg in the RDN group and ‐1.6 ± 19.7 mmHg in the sham group, P = 0.039 for RDN versus sham control during night‐time after Analysis of Covariance (ANCOVA) adjustment for baseline SBP. </p> </section> <section id="CD011499-sec-0060"> <h5 class="title">Office BP</h5> <p>Office blood pressure (BP) was measured in 11 studies (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). In a meta‐analysis of nine studies (10 subgroups) (1090 participants) (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), renal denervation had little or no effect on systolic office BP when compared with sham procedure or standard therapy (MD ‐5.92 mmHg, 95% CI ‐12.94 to 1.10; <a href="./references#CD011499-fig-0014" title="">Analysis 1.11</a>); there was high heterogeneity (Chi² = 64.48; P &lt; 0.00001; I² = 86%). Performing subgroup analyses, benefits on systolic office BP became evident in studies using a multi‐electrode radiofrequency catheter (MD ‐5.10 mmHg, 95% CI ‐9.14 to ‐1.06) compared to in those using a single‐electrode catheter system, nullifying also the heterogeneity among studies (I² = 0%). In data pooled from eight studies (nine subgroups) (1049 participants) (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>), renal denervation may reduce diastolic office BP when compared with sham or standard therapy (MD ‐4.61 mmHg, 95% CI ‐8.23 to ‐0.99; <a href="./references#CD011499-fig-0015" title="">Analysis 1.12</a>); there was high heterogeneity (Chi² = 34.20; P &lt; 0.0001; I² = 77%) that was completely nullified after excluding studies performing ablations with a single‐electrode catheter system (I² = 0%). </p> <p>In <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>, spironolactone addition was more effective than RD in reducing office SBP, ‐29.4 (‐40.7 to ‐18.1) versus ‐17.5 (‐29.7 to ‐5.1) and DBP, ‐12.7 (‐20.0 to ‐5.5) versus ‐7.5 (‐15.5 to 0.5), respectively. Similarly, <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a> showed better efficacy of spironolactone addition than RD in office BP reduction. At 24‐month follow‐up, office systolic/diastolic BP decreased by ‐19.9/‐9.2 mmHg (P = 0.007/P = 0.04) in the RD group versus ‐17.8/‐15.8 mmHg (P = 0.005/P &lt; 0.001) in the spironolactone group. <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a> recorded a greater average diastolic office BP reduction in the renal denervation group than in the control group, with a change difference of ‐6.9 mmHg (95% CI ‐13.2 to 0.5; P = 0.036). These data were obtained from the correspondent study articles. </p> </section> <section id="CD011499-sec-0061"> <h5 class="title">Home BP</h5> <p>In <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>, no change difference in home systolic and diastolic BP was observed between the renal denervation and control groups (‐5.6 mmHg (95% CI ‐14.5 to 3.2; P = 0.205) and ‐4.8 mmHg (95% CI ‐9.8 to 0.3; P = 0.065), respectively). In <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>, the mean change in home systolic and diastolic BP was ‐15.4 mmHg (95% CI ‐20.4 to ‐10.4) and ‐8.7 mmHg (95% CI ‐12.1 to ‐5.4) in patients undergoing renal denervation and ‐11.8 mmHg (95% CI ‐16.5 to ‐7.1) and ‐6.7 mmHg (95% CI‐9.8 to ‐3.5) in the control group, with no differences between groups (P = 0.30 and P = 0.37) for systolic and diastolic BP, respectively. </p> </section> <section id="CD011499-sec-0062"> <h5 class="title">Left ventricular hypertrophy (LVH)</h5> <p>Data on left ventricular mass (LVM) and LVM indexed (LVMI) were provided by four studies (<a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). In data pooled from two studies, renal denervation had little or no effect over sham or standard treatment on LVMI (MD ‐2.34, 95% CI ‐12.93 to 8.25; <a href="./references#CD011499-fig-0016" title="">Analysis 1.13</a>); there was no heterogeneity (Chi² = 0.02; P = 0.89; I² = 0%; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). </p> <p><a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a> recorded no differences in LVMI between RD (mean difference 1.83 g/m<sup>2</sup>; 95% CI −16.6 to 20.2) and spironolactone addition groups (mean difference −5.41 g/m<sup>2</sup>; 95% CI −23.0 to 12.2). <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a> provided 24‐month follow‐up data on LVM and LVMI, reporting a reduction from baseline in the RD group (LVM mean difference ‐50 g [95% CI ‐83 to ‐17, P = 0.007; LVMI ‐10.5 g/m<sup>2</sup> 95% CI ‐17.3 to ‐3.8, P = 0.007]). No changes in LVM and LVMI were recorded in the control group. </p> </section> <section id="CD011499-sec-0063"> <h5 class="title">Obstructive sleep apnoea (OSA) severity</h5> <p>Data on obstructive sleep apnoea (OSA) were only available in <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>. Three months after the procedure, the RDN group showed a decrease in OSA severity as evaluated by apnea hypopnea index (AHI) (from 39.4 ± 25.5 to 31.2 ± 23.4 events/hour; P = 0.015), whereas no difference from baseline in the control group (AHI, 31.6 ± 19.1 versus 30.4 ± 22.3 events/hours) were observed. </p> </section> <section id="CD011499-sec-0064"> <h5 class="title">Kidney function</h5> <p>In a meta‐analysis of five studies (721 participants), renal denervation may result in little or no difference over sham or standard treatment on serum creatinine levels (MD 0.03 mg/dL, 95% CI ‐0.06 to 0.13; <a href="./references#CD011499-fig-0017" title="">Analysis 1.14</a>), with a moderate level of heterogeneity (Chi² = 12.63; P = 0.01; I² = 68%), which could not be further explored, as only five studies were included (<a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). Nevertheless, <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a> reported five cases in the renal denervation group and one case in the sham group, who had an increase in serum creatinine levels greater than 50% from baseline. One case of 50% increase in serum creatinine was also reported in the renal denervation group after six months of follow‐up in <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>. </p> <p>In another meta‐analysis of six studies (822 participants), renal denervation had little or no effect on renal function, as estimated by eGFR or creatinine clearance, as compared to control (MD ‐2.56 mL/min, 95% CI ‐7.53 to 2.42; <a href="./references#CD011499-fig-0018" title="">Analysis 1.15</a>), with moderate heterogeneity (Chi² = 10.02, P = 0.07; I² = 50%), which could not be further explored (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). </p> <p>In <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>, no change from baseline in serum creatinine and creatinine clearance was observed between the RD (SCr: mean difference 0.9 µmol/L (95% CI ‐7.3, 9.2; P = 0.81); CrCl ‐0.5 mL/s/1.73m<sup>2</sup> (95% CI ‐1.3, 0.3, P = 0.21) and control group (SCr 5.7 µmol/L (95% CI ‐0.4, 11.9; P = 0.06); CrCl ‐0.3 mL/s/1.73m<sup>2</sup> (95% CI ‐0.5, 0.01; P = 0.06), respectively. </p> <p><a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a> observed a greater renal function decline in the spironolactone with respect to RDN group; eGFR: mean difference ‐13.7 mL/min/1.73m<sup>2</sup> (95% CI ‐20.0 to ‐7.4) versus ‐3.0 (95% CI ‐9.8 to 3.9); SCr: 14.9 µmol/L (7.4 to 22.4) versus 5.9 (‐2.3 to 14.1). Otherwise, <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a> recorded a decrease in UAE: −87.2 (95% CI −164.5 to −9.9) in the spironolactone compared with the RD group: −23.8 mg/g (95% CI −104.5 to 56.9), at six months.  </p> </section> <section id="CD011499-sec-0065"> <h5 class="title">Metabolic profile</h5> <p>Only <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> reported information on glucose metabolism measures. After three months, there were no changes in fasting plasma glucose (RD, from 6.8 to 7.1 mmol/L; control group, from 6.7 to 6.7 mmol/L), insulin concentration (RD, from 13.4 to 12.8 mmol/L; control group, from 12.5 to 12.0 mmol/L) and glycosylated haemoglobin (RD, from 6.3 to 6.5%; control group, from 6.4 to 6.5%) in either group. </p> </section> <section id="CD011499-sec-0066"> <h5 class="title">Adverse events</h5> <p>Major adverse events were systematically collected by 11 studies (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a> registered 36 serious adverse events (n = 24, 26% in the intervention group and n = 12, 27% in the usual care group) and 17 periprocedural complications, including vascular (n = 4), bleeding (n = 8) and five other mild complications (back pain, groin pain and hypotension in the RD group. <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a> recorded minor symptoms, such as headache, atypical chest pain, muscle convulsions and fatigue in five RD and six SHAM patients, respectively. <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a> observed that mild groin haematoma and transient symptomatic hypotension developed in five patients in the RD group; one patient in the spironolactone group reported hyponatraemia, muscle cramps, and transient symptomatic hypotension. <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a> and <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a> reported no periprocedural complications in either the RD or control arms. No study provided information on the occurrence of transient dizziness or anaemia. </p> <section id="CD011499-sec-0067"> <h6 class="title">Bradycardia</h6> <p>In a meta‐analysis of three studies (220 participants), renal denervation may increase the risk of bradycardia occurrence than other treatments (RR 6.63, 95% CI 1.19 to 36.84; <a href="./references#CD011499-fig-0019" title="">Analysis 1.16</a>), with no heterogeneity (Chi² = 0.63; P = 0.73; I² = 0%; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>). <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> observed five episodes of bradycardia in the whole study population. </p> </section> <section id="CD011499-sec-0068"> <h6 class="title">Femoral artery pseudoaneurysm</h6> <p>Pooled data from two studies (201 participants) showed that renal denervation may have little or no effect on the risk for femoral artery pseudoaneurysm compared to standard therapy (RR 3.96, 95% CI 0.44 to 35.22; <a href="./references#CD011499-fig-0020" title="">Analysis 1.17</a>), with no heterogeneity (Chi² = 0.04; P = 0.84; I² = 0%; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>). <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a> observed two cases of spurious aneurysm in the RD group. </p> </section> <section id="CD011499-sec-0069"> <h6 class="title">Renal artery dissection</h6> <p>In <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>, there was one case of renal artery dissection related to the procedure. </p> </section> <section id="CD011499-sec-0070"> <h6 class="title">Renal artery vasospasm</h6> <p>Four cases of renal artery vasospasm in patients undergoing renal denervation were observed in <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>. <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a> reported one case of transient renal artery spasm which occurred after radiofrequency application. </p> </section> <section id="CD011499-sec-0071"> <h6 class="title">New renal‐artery stenosis</h6> <p><a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a> reported one case of re‐stenosis in the renal denervation group (documented as new renal artery stenosis of more than 70%) within the six‐month follow‐up. </p> </section> <section id="CD011499-sec-0072"> <h6 class="title">Flank pain</h6> <p>In a meta‐analysis of two studies (199 participants), renal denervation  may have little or no effect on the risk of flank pain compared to control (RR 4.30, 95% CI 0.48 to 38.28; <a href="./references#CD011499-fig-0021" title="">Analysis 1.18</a>), with no heterogeneity (Chi² = 0.08; P = 0.78; I² = 0%; <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>). </p> </section> <section id="CD011499-sec-0073"> <h6 class="title">Pitting oedema</h6> <p>One case of oedema requiring hospital admission was recorded in <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>. </p> </section> <section id="CD011499-sec-0074"> <h6 class="title">Hypotensive episodes</h6> <p>In a meta‐analysis of three studies (143 participants), the renal denervation procedure had little or no effect on the risk of hypotensive episodes compared to no treatment (RR 1.60, 95% CI 0.20 to 12.63; <a href="./references#CD011499-fig-0022" title="">Analysis 1.19</a>); the analysis had moderate heterogeneity (Chi² = 4.77; P = 0.09; I² = 58%; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>). </p> </section> <section id="CD011499-sec-0075"> <h6 class="title">Hypertensive crisis</h6> <p>In data pooled from three studies (722 participants), renal denervation had little or no effect on the risk of hypertensive episodes as compared with controls (RR 0.71, 95% CI 0.35 to 1.45; <a href="./references#CD011499-fig-0023" title="">Analysis 1.20</a>), with no heterogeneity (Chi² = 1.83; P = 0.40; I² = 0%; <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>). </p> </section> <section id="CD011499-sec-0076"> <h6 class="title">Hyperkalaemia</h6> <p>In a meta‐analysis of three studies (224 participants), the denervation procedure had little or no effect on the risk of hyperkalaemia compared to standard therapy (RR 0.43, 95% CI 0.05 to 3.89; <a href="./references#CD011499-fig-0024" title="">Analysis 1.21</a>). There was low heterogeneity in this analysis (Chi² = 3.17; P = 0.21; I² = 37%), which could not be further explored, as only three studies were included (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>). </p> </section> <section id="CD011499-sec-0077"> <h6 class="title">Syncope</h6> <p>In <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>, one patient in the control group experienced an episode of syncope. In <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>, no syncope occurred in either group. </p> </section> <section id="CD011499-sec-0078"> <h6 class="title">Embolic events</h6> <p>In <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>, one case of embolic event resulting in end‐organ damage was reported in the renal denervation group. </p> </section> <section id="CD011499-sec-0079"> <h6 class="title">Withdrawals</h6> <p>Twelve studies provided information on withdrawals (<a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a>; <a href="./references#CD011499-bbs2-0002" title="De La SierraA , ParejaJ , ArmarioP , BarreraA , SansL , VazquezS , et al. Renal denervation versus spironolactone in resistant hypertension. effects on circadian patterns and blood pressure variability. Journal of Hypertension2016;34(Suppl 2):e43. De la SierraA , ParejaJ , ArmarioP , BarreraA , YunS , VazquezS , et al. Renal denervation vs. spironolactone in resistant hypertension: effects on circadian patterns and blood pressure variability. American Journal of Hypertension2017;30:37-41. NCT02039492. Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension [Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension]. clinicaltrials.gov/show/NCT02039492 (first received 2012). Oliveras A, Armario P, ClaraA , Sans-Atxer L, Vazquez S, PascualJ ,  et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. Journal of Hypertension2016;34:1863–71. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone: the DENERVHTA (Denervacion en Hipertension Arterial) study. Journal of Clinical Hypertension2018;20(1):69-75. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaL , et al. Preclinical target organ damage changes in patients with resistant hypertension randomized to renal denervation or spironolactone as add-on therapy. results from the DENERVHTA study. Hypertension 2016;68(Suppl 1):10. OliverasA , ArmarioP , SansL , ClaraA , VazquezS , MolinaLL , et al. Changes in subclinical organ damage in patients with resistant hypertension randomized to receive renal denervation or spironolactone as add-on therapy.the Denervhta study results. Journal of Hypertension2016;34(Suppl 2):e47. ">DENERVHTA</a>; <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>; <a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>; <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a>; <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>; <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). <a href="./references#CD011499-bbs2-0015" title="BakrisGL , TownsendRR , FlackJM , BrarS , CohenSA , D'Agostino, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. Journal of the American College of Cardiology2015;65:1314-21. BakrisGL , TownsendRR , LiuM , CohenSA , D'AgostinoR , FlackJM , et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. Journal of the American College of Cardiology2014;64:1071-8. BhattDL , BakrisGL . Long-term (24-month) blood pressure results of catheter-based renal artery denervation: SYMPLICITY HTN-3 randomized controlled trial. Journal of the American College of Cardiology2015;1:B38-9. BhattDL , KandzariDE , O'NeillWW , D'AgostinoR , FlackJM , KatzenBT , et al. A controlled trial of renal denervation for resistant hypertension. New England Journal of Medicine2014;370:1393-401. BhattDL , KandzariDE , O'NeillWW . A controlled trial of renal denervation for resistant hypertension. Journal of Vascular Surgery2014;60:266. DivisonJA , EscobarCC , SeguiDM . Controlled clinical trial on renal denervation in resistant hypertension. Semergen2014;40:345-6. FlackJ , BakrisGL , KandzariD , KatzenBT , LeonM , MauriL , et al. SYMPLICITY HTN-3: outcomes in the African-American and Non-African American populations. Journal of the American College of Cardiology2014;1:B119-20. FlackJM , BhattDL , KandzariDE , BrownD , BrarS , ChoiJ , et al. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. Journal of the American Society of Hypertension2015;9:769-79. KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36:219-27. KandzariDE , BhattDL , SobotkaPA , O'NeillWW , EslerM , FlackJM , et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clinical Cardiology2012;35:528-35. KarioK , BakrisG , PocockS , FahyM , BhattDL . Changes in nocturnal blood pressure post-renal denervation: comparison of treatment versus control groups in SYMPLICITY HTN-3. European Heart Journal2019;40 Suppl 1:664. KarioK , BakrisGL , BhattD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33 Suppl 1:e52. KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. KarioK , BhattDL , TownsendR , FlackJ , NegoitaM , OparilS , et al. Potential reduction in office and nocturnal blood pressure after renal denervation in patients with obstructive sleep apnea: A subgroup analysis of SYMPLICITY HTN-3. European Heart Journal2015;36:186. NCT01418261. SYMPLICITY HTN-3 renal denervation in patients with uncontrolled hypertension  [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3)]. clinicaltrials.gov/show/NCT01418261 (first received 2011). PekarskiyS , BaevA , MordovinV , SitkovaE , SemkeG , RippT , et al. Failure of renal denervation in SYMPLICITY HTN-3 is a predictable result of anatomically inadequate operative technique and not the true limitations of the technology. Journal of Hypertension2015;33 Suppl 1:e108. ">SYMPLICITY HTN‐3 2014</a> recorded 14 (3.8%) withdrawals from the renal denervation group and two (1.2%) from the control arm. In <a href="./references#CD011499-bbs2-0014" title="BoehmM , SchlaichMP , KrumH , SchmiederRE , SobotkaP , EslerMD . One-year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: from the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:770. EslerM , KrumH , SchmiederR , BohmM . Renal sympathetic denervation for treatment of resistant hypertension: Two-year update from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2013;1:E1386. EslerMD , BohmM , SievertH , RumpCL , SchmiederRE , KrumH , et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36-month results from the SYMPLICITY HTN-2 randomized clinical trial. European Heart Journal2014;35:1752-9. EslerMD , KrumH , SchlaichM , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMPLICITY HTN-2 randomized, controlled trial. Orvosi Hetilap2014;155(21):843. [DOI: 10.1556/OH.2014.21M]EslerMD , KrumH , SchlaichM , SchmiederR , BohmM , SobotkaP . Renal sympathetic denervation for treatment of resistant hypertension: One year results from the SYMPLICITY HTN-2 randomized controlled trial. Journal of the American College of Cardiology2012;1:E1705. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the SYMLICITY HTN-2 randomized, controlled trial. Circulation2012;126:2976-82. EslerMD , KrumH , SchlaichM , SchmiederRE , BohmM , SobotkaPA , et al. SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. Circulation2010;122:2220. EslerMD , KrumH , SchlaichMP , SchmiederRE , BoehmM , SobotkaP . Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18-month follow-up of the SYMPLICITY HTN-2 trial. European Heart Journal2012;33:181. EslerMD , KrumH , SchlaichMP , SchmiederRE , BohmM . Persistent and safe blood pressure lowering effects of renal artery denervation: three-year follow-up from the SYMPLICITY HTN-2 trial. Journal of the American College of Cardiology2013;1:B19. MurrayE , HenryK , MarcusS , RolandS , MichaelB . Long-term follow-up of catheter-based renal denervation in patients with treatment resistant hypertension: the SYMPLICITY HTN-2 trial. Journal of Clinical Hypertension2013;15(Suppl 1):28. NCT00888433. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2) [Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-2)]. clinicaltrials.gov/show//NCT00888433 (first received 2009). Symplicity HTN-2 Investigators, EslerMD , KrumH , SobotkaPA , SchlaichMP , SchmiederRE , et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet2010;376(9756):1903-9. [DOI: 10.1016/S0140-6736(10)62039-9]UkenaC , MahfoudF , EwenS , KindermannI , BoehmM . Cardiorespiratory response to exercise after renal sympathetic denervation in resistant hypertension. Cardiology (Switzerland)2013;125:158. UkenaC , MahfoudF , KindermannI , BarthC , LenskiM , KindermannM , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. Journal of the American College of Cardiology2011;58:1176-82. UkenaC , MahfoudF , KindermannI , KindermannM , BrandtMC , HoppeU , et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. European Heart Journal2011;32:960. ">SYMPLICITY HTN‐2 2010</a>, there were three withdrawals from both the intervention and control arms. <a href="./references#CD011499-bbs2-0001" title="AziziM , SapovalM , GosseP , MongeM , BobrieG , DelsartP , et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENER-HTN): a multicentre, open-label, randomised controlled trial. Lancet2015;385(9981):1957-65. ForniO , PereiraV , SapovalE , AziziM . Prevalence and risk factors for refractory hypertension in the DENER-HTN study. Journal of Hypertension2015;33:e51. NCT01570777. Renal denervation in hypertension [Renal denervation in patients with resistant hypertension ]. clinicaltrials.gov/show/NCT01570777 (first received 2 April 2012). SapovalMR , MongeM , PereiraH , AziziM . DENER-HTN trial: a prospective randomized control trial of the efficacy of renal artery denervation in resistant hypertension. Cardiovascular and Interventional Radiology2014;1:S341. ">DENER‐HTN 2015</a> reported five (10%) withdrawals from the renal denervation group. In <a href="./references#CD011499-bbs2-0003" title="DeschS , OkonT , HeinemannD , KulleK , RohnertK , SonnabendM , et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension2015;65:1202-8. FenglerK , HeinemannD , OkonT , RöhnertK , StiermaierT , Von RöderM , et al. Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial. Clinical Research in Cardiology2016;105(7):592–600. [DOI: 10.1007/s00392-015-0955-8]NCT01656096. Renal sympathetic denervation in mild refractory hypertension [Renal sympathetic denervation in patients with mild refractory hypertension]. clinicaltrials.gov/show/NCT01656096 (first received 31 July 2012). ">Desch 2015</a>, six participants (17%) withdrew from the renal denervation and two (5.55%) from the sham group. <a href="./references#CD011499-bbs2-0010" title="NCT01560312. Renal denervation in refractory hypertension [Renal denervation - hope for patients with refractory hypertension?]. clinicaltrials.gov/show/NCT01560312 (first received 16 May 2011). RosaJ , WidimskyP , TousekP , PetrakO , CurilaK , WaldaufP , et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension2015;65:407-13. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension2016;67:397-403. RosaJ , WidimskyP , WaldaufP , LambertL , ZelinkaT , TaborskyM , et al. The role of adding spironolactone and renal denervation in true resistant hypertension. One-year outcomes of randomized study. European Heart Journal2016;37 Suppl 1:230. RosaJ , WidimskyP , WaldaufP , ZelinkaT , PetrakO , TaborskyM , et al. Renal denervation in comparison to intensified pharmacotherapy in true resistant hypertension. Two-year outcomes of randomised PRAGUE-15 study. European Heart Journal2017;38 Suppl 1:157. RosaJ , WidmskyP , WaldaufP , ZelinkaT , PetakO , TaborskyM , et al. Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. Journal of Hypertension2017;35:1093–9. RosaJ , ZelinkaT , PetrakO , StrauchB , SomloovaZ , IndraT , et al. Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?Journal of Human Hypertension2014;28:684-8. TousekP , WidimskyJ , RosaJ , CurilaK , BrannyM , NyklI , et al. Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: rationale and design of a multicenter randomized study - PRAGUE-15. Cor et Vasa2014;56:e235-9. ">Prague‐15</a> recorded seven (13.7%) and 31 (62%) withdrawals from the renal denervation and control groups, respectively. Three studies reported no withdrawals (<a href="./references#CD011499-bbs2-0005" title="KarioK , BakrisG , BhattLD . Preferential reduction in morning/nocturnal hypertension by renal denervation for drug-resistant hypertension: a new ABPM analysis of SYMPLICITY HTN-3 and HTN-Japan. Journal of Hypertension2015;33(Suppl 1):e52. [DOI: 10.1097/01.hjh.0000467484.20438.39]KarioK , BhattDL , BrarS , CohenSA , FahyM , BakrisGL . Effect of catheter-based renal denervation on morning and nocturnal blood pressure: insights from SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension2015;66:1130-7. [EMBASE: 10.1161/HYPERTENSIONAHA.115.06260]KarioK , OgawaH , OkumuraK , OkuraT , SaitoS , UenoT , et al. SYMPLICITY HTN-Japan - First randomized controlled trial of catheter-based renal denervation in Asian patients. Circulation Journal2015;79:1222-9. NCT01644604. Renal denervation by MDT-2211 system in patients with uncontrolled hypertension [The clinical study of renal denervation by MDT-2211 system in patients with uncontrolled hypertension]. clinicaltrials.gov/show/NCT01644604 (first received 29 June 2012). ">HTN‐JAPAN 2015</a>; <a href="./references#CD011499-bbs2-0009" title="Bergland OU , Søraas CL , Larstorp ACK, HalvorsenLV , HjørnholmU , HoffmanP , et al. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up. Blood Pressure2020;30:41-50. BergoKK , LarstorpAC , HoffmannP , HjørnholmU , CataliottiA , HøieggenA , et al. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. Blood pressure2020;30:31-40. ElmulaMF , HoffmannP , LarstorpAC , BrekkeM , FossumE , StenehjemA , et al. Renal sympathetic denervation is inferior to adjusted drug treatment in patients with true treatment resistant hypertension, a randomized controlled trial. European Heart Journal2014;35:718. ElmulaMF , HoffmannP , LarstorpAC , FossumE , BrekkeM , KjeldsenSE , et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension2014;63:991-9. ElmulaMF , HoffmannP , LarstorpAC , HoieggenA , KjeldsenS . Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment resistant hypertension, a randomized clinical trial. Journal of the American College of Cardiology2014;1:A1306. ElmulaMF , LarstorpAC , HoffmannP , RostrupM , HoieggenA , KjeldsenS . One-year outcomes of a randomized study in renal denervation: Results for Oslo-RDN study. European Heart Journal2016;37(Suppl 1):1056-7. LarstorpBK , HoieggenACK , HjornholmA , RostrupP , ElmulaMF . Haemodynamic changes in patients with treatment-resistant hypertension after renal sympathetic denervation compared to individualized drug therapy. Journal of hypertension2016;34(Suppl 2):e305. NCT01673516. Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography [Effect of renal sympathetic denervation on resistant hypertension and cardiovascular hemodynamic in comparison to intensive medical therapy utilizing impedance cardiography]. clinicaltrials.gov/show/NCT01673516 (first received 17 August 2012). SoeraasCL , BerglandO , HalvorsenLV , LarstorpAC , HjornholmU , KjaerVN , et al. Long-term outcome of the randomized Oslo-RDN study. Journal of hypertension2018;36 Suppl 1:e238-9. ">Oslo RDN 2014</a>; <a href="./references#CD011499-bbs2-0012" title="EngholmM , BertelsenJB , MathiassenON , BotkerHE , VaseH , PetersCD , et al . Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial. International Journal of Cardiology2018;250:29-34. MathiassenO , BechJN , BuusNH , ChristensenKL , VaseH , BertelsenJB , et al. Renal sympathetic denervation in treatment resistant essential hypertension. A sham-controlled, double-blinded randomized trial (ReSET trial). Journal of the American College of Cardiology2015;66:B41. MathiassenON , VaseH , BechJN , ChristensenKL , BuusNH , SchroederAP , et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. Journal of Hypertension2016;34:1639–47. NCT01459900. Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial [Renal sympathectomy in treatment resistant essential hypertension: a sham controlled randomized trial]. clinicaltrials.gov/show/NCT01459900 (first received 2011). PetersCD , MathiassenON , VaseH , NorgaardBJ , ChristensenKL , SchroederAP , et al. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Pressure2017;26:366-80. ">ReSET 2015</a>). <a href="./references#CD011499-bbs2-0013" title="deBeusE , deJagerRL , BeeftinkMM , SandersMF , SpieringW , VonkenEJ , et al. Salt intake and blood pressure response to percutaneous renal denervation in resistant hypertension. Journal of Clinical Hypertension2017;19:1125-33. deJagerRL , deBeusE , BeeftinkMMA , SandersMF , VonkenEJ , VoskuilM , et al. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension2017;69(4):678-84. NCT01850901. Renal sympathetic denervation as a new treatment for therapy resistant hypertension  [Renal sympathetic denervation as a new treatment for therapy resistant hypertension - a multicenter randomized controlled trial]. clinicaltrials.gov/show/NCT01850901 (first received 2013). VinkEE , De BeusE , De JagerRL , VoskuilM , SpieringW , VonkenEJ , et al. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. American Heart Journal2014;167:308-14.e3. ">SYMPATHY</a> recorded eight withdrawals (5.8%) (five in the RDN and three in the usual care group). </p> </section> </section> <section id="CD011499-sec-0080"> <h5 class="title">Outcomes not stated</h5> <p>No RCT provided data on the following outcomes: fatal cardiovascular events, need for renal replacement therapy and proteinuria. </p> </section> <section id="CD011499-sec-0081"> <h5 class="title">Sensitivity analyses, investigation of heterogeneity, and publication bias</h5> <p>Such investigations were not performed due to the small number of studies retrieved.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011499-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011499-sec-0082"></div> <section id="CD011499-sec-0083"> <h3 class="title" id="CD011499-sec-0083">Summary of main results</h3> <p>In patients with resistant hypertension, a renal denervation procedure may have little or no effect on the risk of major cardiovascular events, including myocardial infarction, ischaemic stroke, and unstable angina, as well as hospital admission, compared with controls. Nevertheless, this procedure may decrease 24‐hour ABPM and office diastolic blood pressure. Little or no effect was observed on renal function, while it likely increases the risk of bradycardia episodes. Renal denervation had little or no effect on the risk of other adverse effects, such as femoral artery pseudo‐aneurysm, flank pain, hypotensive or hypertensive episodes, and long‐term hyperkalaemia. Data on mortality and other adverse effects were limited to single studies. </p> </section> <section id="CD011499-sec-0084"> <h3 class="title" id="CD011499-sec-0084">Overall completeness and applicability of evidence</h3> <p>Our findings suggest that RD could be effective for blood pressure control and be safe, with a low complications and adverse events rate. Nevertheless, many clinically relevant outcomes, such as fatal cardiovascular events, quality of life, sleep apnoea severity, need for renal replacement therapy and metabolic profile, were absent or poorly explored in some included RCTs. Heterogeneity was high in the majority of analyses carried out, hampering the overall reliability of findings. Although exploration of heterogeneity was not feasible in the majority of analyses, due to the paucity of studies included, it can be speculated that differences among individual study designs (e.g. use of sham procedure or standard therapy as control, presence or absence of blinding in outcome assessment, use of multiple catheter systems) may represent one of the main causes underlying this phenomenon. In most trials, both study groups were simultaneously treated with optimal antihypertensive therapy to decrease blood pressure to an established target. Administration of these drugs was variable and non‐reproducible. Procedural methods were also heterogeneous among studies, particularly in terms of type of catheter employed, number of applications, energy delivered and target portion of the renal artery. Sakakura and colleagues recently observed that nervous fibres are mostly concentrated in the middle and proximal segments of the renal artery while their number decrease in the distal segment (<a href="./references#CD011499-bbs2-0203" title="SakakuraK , LadichE , ChengQ , OtsukaF , YahagiK , FowlerDR , et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. Journal of the American College of Cardiology2014;64(7):635-43.">Sakakura 2014</a>). Previous data evidenced a maximum procedural efficacy after ablation in the whole circumference of the renal artery and a dose‐response dependency directly related to the amount of energy delivered (<a href="./references#CD011499-bbs2-0197" title="KandzariDE , BhattDL , BrarS , DevireddyCM , EslerM , FahyM , et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. European Heart Journal2015;36(4):219-27.">Kandzari 2015</a>). The lack of standardised methods for renal denervation may hamper the reliability of comparisons among studies and, in some cases, even raise the question as to whether the procedure was truly successful (<a href="./references#CD011499-bbs2-0189" title="EslerM . Renal denervation: not as easy as it looks. Science Translational Medicine2015;7(285):285fs18.">Esler 2015</a>). Our results show a greater decrease in office and 24h ABPM among patients who underwent the multi‐electrode catheter denervation system, performing four ablations simultaneously delivered at the mid/distal segment of the renal artery, compared to the first generation procedures (radiofrequency ablation via single‐electrode catheter). Type of ablation therapy employed and target sites for ablation must be explored in future trials. The available evidence suggests that RD could be effective optimising the procedure by carefully selecting patients with truly resistant hypertension and applying new methods and technologies guided by a better understanding of renal nerve anatomy. </p> </section> <section id="CD011499-sec-0085"> <h3 class="title" id="CD011499-sec-0085">Quality of the evidence</h3> <p>The GRADE quality of the evidence (<a href="./references#CD011499-bbs2-0192" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>) was low for cardiovascular morbidity outcomes and adverse effects, moderate for blood pressure and renal function outcomes and low to very low for the remaining outcomes. The quality of evidence was mostly influenced by the imprecision of results (wide confidence intervals) or the low number of studies providing quantitative data on the same outcome, or both. Of note, although few studies were at high risk of bias for allocation concealment or blinding, in the majority of the included studies, the risk of bias remained unclear for most items, making it therefore difficult to evaluate the impact on the quality of evidence.  </p> </section> <section id="CD011499-sec-0086"> <h3 class="title" id="CD011499-sec-0086">Potential biases in the review process</h3> <p>Points of strength of this review are represented by a peer‐reviewed protocol, a systematic search of electronic databases, and data extraction, analysis, and risk of bias assessment completed independently by two authors, according to current methodological standards. The main limitation is represented by the data obtainable from the included studies. Studies were mainly focussed on small populations and short treatment periods. As a result, most trials were not adequately powered to capture exhaustive information on hard, patient‐centred outcomes, such as fatal or non‐fatal cardiovascular events. Moreover, use of multiple catheter systems could potentially contribute to the heterogeneity observed in our analysis. </p> </section> <section id="CD011499-sec-0087"> <h3 class="title" id="CD011499-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>In a previous systematic review, renal denervation was apparently efficacious in reducing mean blood pressure at six months in individuals with resistant hypertension (RH) (<a href="./references#CD011499-bbs2-0188" title="DavisMI , FilionKB , ZhangD , EisenbergMJ , AfilaloJ , SchiffrinEL , et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. Journal of the American College of Cardiology2013;16(3):231-41.">Davis 2013</a>). Unfortunately, this review was mostly based on data from observational, uncontrolled studies with limited follow‐up, small sample sizes and high heterogeneity in blood pressure measurement. Conversely, two of the most recent meta‐analyses (<a href="./references#CD011499-bbs2-0190" title="Fadl ElmulaM ,  Feng Y-M,  JacobsL ,  LarstorpAC ,  KjeldsenSE ,  PersA ,  European Network COordinating research on Renal Denervation (ENCOReD). Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Pressure2017;26(4):195-203.">Fadl Elmula 2017</a> and <a href="./references#CD011499-bbs2-0186" title="AgasthiP , ShipmanJ , ArsanjaniR , AshukemM , GirardoME , YerasiC , et al. Renal denervation for resistant hypertension in the contemporary era: a systematic review and meta-analysis. Scientific Reports2019;9(1):6200.">Agasthi 2019</a>) that included RCTs did not show any significant effect on blood pressure in patients with RH following renal denervation. The authors confirmed the lack of evidence supporting a widespread use of this procedure in clinical practice, advocating for future clinical trials with a longer observation time, sham control study design and novel renal denervation techniques. Over the past year, multiple randomised controlled trials evaluating the effect of RD on RH patients showed promising results (<a href="./references#CD011499-bbs2-0006" title="JacobsL , PersuA , HuangQF , LengeleJP , ThijsL , HammerF , et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Pressure2017;26(6):321-31. JinY , JacobsL , BaelenM , ThijsL , RenkinJ , HammerF , et al. Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Blood Pressure2014;23:138-46. JinY , JocobsL , HammerF , RenkinJ , PersuA , StaessenJA . Rationale and design of the investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) trial. Journal of the American Society of Hypertension2014;8(S4):e71. NCT01505010. Renal denervation for management of drug-resistant hypertension  [Investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension ]. clinicaltrials.gov/show/NCT01505010 (first received 2012). ">INSPIRED</a>; <a href="./references#CD011499-bbs2-0007" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  Sapojnic N, et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;26:P711. MoiseevaA , CarausA , CiobanuN , MoscaluV , SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐B</a>; <a href="./references#CD011499-bbs2-0008" title="MoiseevaA ,  CarausA ,  MoscaluV ,  CaleniciO ,  CiobanuN ,  SapojnicN ,  et al. The influence of renal denervation treatment on blood pressure in patients with resistant hypertension. European Journal of Preventive Cardiology2020;27(1 Suppl 1):P711. MoiseevaA , CarausA , Ciobanu N Moscalu V, SurevA , AbrasM , et al. The effects of renal artery denervation on blood pressure values and diastolic dysfunction in resistant hypertension. European Journal of Preventive Cardiology2019;26(Suppl 1):S164-5. ">Moiseeva 2020‐M</a>; <a href="./references#CD011499-bbs2-0016" title="NCT01366625. Renal denervation in patients with resistant hypertension and obstructive sleep apnea [Effects of renal denervation on blood pressure and clinical course of obstructive sleep apnea in patients with resistant hypertension]. clinicaltrials.gov/show/NCT01366625 (first received 2011). Warchol-CelinskaE , PrejbiszA , KadzielaJ , FlorczakE , JanuszewiczM , MichalowskaI , et al. Renal Denervation in Resistant Hypertension and Obstructive Sleep Apnea: Randomized Proof-of-Concept Phase II Trial. Hypertension2018;72:381-90. Warchol-CelinskaE , PrejbiszA , KadzielaJ , SliwinskiP , PlywaczewskiR , FlorczakE , et al. Effect of renal denervation on blood pressure levels and clinical course of obstructive sleep apnea in patients with resistant hypertension-3 months outcomes of randomized trial. European Heart Journal2016;37 Suppl 1:793. WarcholE , PrejbiszA , KadzielaJ , FlorczakE , KabatM , SliwinskiP , et al. The impact of renal sympathetic denervation on office and ambulatory blood pressure levels in patients with true resistant hypertension and obstructive sleep apnea: the interim analysis. European Heart Journal2014;35:231. ">Warchol 2014</a>). Our meta‐analysis of high‐quality RCTs showed significant benefits of this procedure over sham/medical therapy in reducing 24‐hour ABPM and office diastolic blood pressure. Moreover, patients who underwent RD had no significant changes in renal function, supporting the safety profile of the procedure. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011499-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011499-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011499-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011499-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 1: Myocardial infarction" data-id="CD011499-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 1: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 2: Ischaemic stroke" data-id="CD011499-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 2: Ischaemic stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 3: Unstable angina" data-id="CD011499-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 3: Unstable angina</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 4: Hospital admission" data-id="CD011499-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 4: Hospital admission</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 5: Systolic 24‐hour ABPM" data-id="CD011499-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 5: Systolic 24‐hour ABPM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 6: Diastolic 24‐hour ABPM" data-id="CD011499-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 6: Diastolic 24‐hour ABPM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 7: Systolic daytime ABPM" data-id="CD011499-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 7: Systolic daytime ABPM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 8: Diastolic daytime ABPM" data-id="CD011499-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 8: Diastolic daytime ABPM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 9: Systolic night‐time ABPM" data-id="CD011499-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 9: Systolic night‐time ABPM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 10: Diastolic night‐time ABPM" data-id="CD011499-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 10: Diastolic night‐time ABPM </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 11: Systolic office BP" data-id="CD011499-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 11: Systolic office BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 12: Diastolic office BP" data-id="CD011499-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 12: Diastolic office BP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 13: Left ventricular mass index (LVMI)" data-id="CD011499-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 13: Left ventricular mass index (LVMI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 14: Serum creatinine" data-id="CD011499-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 14: Serum creatinine</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 15: eGFR/creatinine clearance" data-id="CD011499-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 15: eGFR/creatinine clearance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 16: Bradycardia" data-id="CD011499-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 16: Bradycardia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 17: Femoral artery pseudoaneurysm" data-id="CD011499-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 17: Femoral artery pseudoaneurysm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 18: Flank pain" data-id="CD011499-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 18: Flank pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 19: Hypotensive episodes" data-id="CD011499-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 19: Hypotensive episodes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 20: Hypertensive crisis" data-id="CD011499-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 20: Hypertensive crisis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011499-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/urn:x-wiley:14651858:media:CD011499:CD011499-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 21: Hyperkalaemia" data-id="CD011499-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_t/tCD011499-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Renal denervation vs. sham/standard therapy, Outcome 21: Hyperkalaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/media/CDSR/CD011499/image_n/nCD011499-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011499-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Renal denervation versus sham denervation or standard treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with resistant hypertension<br/><b>Setting:</b> outpatient<b> </b> <br/><b>Intervention:</b> renal denervation<br/><b>Comparison:</b> sham procedure or standard treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Effect estimate<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Sham denervation/</b> </p> <p><b>Standard treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Renal denervation</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000 (6 to 54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.31 (0.45 to 3.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>742</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ischaemic stroke</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 1000 (4 to 41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.98 (0.33 to 2.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>892</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unstable angina</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 1000 (2 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.51 (0.09 to 2.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalisation</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>28 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>35 per 1000 (14 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.24 (0.50 to 3.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>743</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>low<sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic 24‐hour ABPM (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic 24‐hour ABPM ranged across control groups from 139 to 157.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic 24‐hour ABPM in the intervention groups was on average <b>5.29 lower</b> (95%CI ‐10.46 to ‐0.13) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1045<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic 24‐hour ABPM (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic 24‐hour ABPM ranged across control groups from 80 to 89.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic 24‐hour ABPM in the intervention groups was on average <b>3.75 lower</b> (95%CI ‐7.10 to ‐0.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1004<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Systolic office BP (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic office BP ranged across control groups from 140 to 165.7</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean systolic office BP in the intervention groups was on average <b>5.92 lower</b> (95%CI ‐12.94 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1090<br/>(9 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diastolic office BP (mmHg)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic office BP ranged across control groups from 83.8 to 99.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean diastolic office BP in the intervention groups was on average <b>4.61 lower</b> (95%CI ‐8.23 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1049<br/>(8 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eGFR or creatinine clearance (mL/min/1.73m²)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean eGFR or creatinine clearance ranged across control groups from 70.59 to 92.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean eGFR or creatinine clearance in the intervention groups was on average <b>2.56 lower</b> (95%CI ‐7.53 to 2.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>822<br/>(6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum creatinine (mg/dL)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum creatinine ranged across control groups from 0.86 to 1.07</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum creatinine in the intervention groups was on average <b>0.03 higher</b> (95%CI ‐0.06 to 0.13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>721<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>moderate<sup>1</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>*The <b>assumed risk</b> is the observed risk in the reference (control) group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>GRADE Working Group grades of evidence<br/><b>High quality</b> : Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality</b> : Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality</b> : Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality</b>: We are very uncertain about the estimate. </p> <p><b>Legend</b><br/><sup>ABPM: ambulatory blood pressure monitoring<br/>BP: blood pressure<br/>CI: confidence interval<br/>CV: cardiovascular<br/>eGFR: estimated glomerular filtration rate<br/>MD: mean difference<br/>NA: information not available (data sparse or absent)<br/>RR: risk ratio</sup>. </p> <p>1. Downgraded 1 level for serious imprecision: Wide confidence intervals</p> <p>2. Downgraded 1 level because outcome reported by less than half of the studies</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/full#CD011499-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011499-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Renal denervation vs. sham/standard therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.45, 3.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Ischaemic stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.33, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Unstable angina <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.09, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.50, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Systolic 24‐hour ABPM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.29 [‐10.46, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Diastolic 24‐hour ABPM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.75 [‐7.10, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Systolic daytime ABPM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.87 [‐5.02, 12.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Diastolic daytime ABPM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [‐3.22, 9.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Systolic night‐time ABPM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐12.74, 9.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Diastolic night‐time ABPM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐9.25, 7.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Systolic office BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.92 [‐12.94, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Diastolic office BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.61 [‐8.23, ‐0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Left ventricular mass index (LVMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.34 [‐12.93, 8.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.06, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 eGFR/creatinine clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.56 [‐7.53, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Bradycardia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.63 [1.19, 36.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Femoral artery pseudoaneurysm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.96 [0.44, 35.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Flank pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.30 [0.48, 38.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Hypotensive episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.20, 12.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Hypertensive crisis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.35, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.05, 3.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Renal denervation vs. sham/standard therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011499.pub3/references#CD011499-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011499.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011499-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011499-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011499-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011499-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD011499-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD011499-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD011499-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011499-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011499\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011499\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011499\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011499\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011499\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011499.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011499.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011499.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011499.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011499.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719420144"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011499.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719420148"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011499.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de8495e09f55b',t:'MTc0MDcxOTQyMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 